What is the first-line antihypertensive medication for patients with end-stage renal disease?

First-Line Antihypertensive in End-Stage Renal Disease (ESRD)

In patients with ESRD on dialysis, prioritize volume management first through ultrafiltration and sodium restriction, then use ACE inhibitors, ARBs, or calcium channel blockers as first-line antihypertensive medications, with beta-blockers as an additional reasonable first-line option, particularly in patients with cardiovascular disease. 1

The Critical Foundation: Volume Management Before Medications

Volume overload is the primary driver of hypertension in dialysis patients 1. Before reaching for antihypertensive medications, you must:

• Optimize ultrafiltration to achieve true dry weight
• Restrict dietary sodium aggressively
• Reassess target dry weight if blood pressure remains elevated despite medication

This is not optional—it's the cornerstone of blood pressure management in ESRD. Only after addressing volume status should you add or uptitrate antihypertensive medications 1.

First-Line Medication Choices

ACE Inhibitors and ARBs

These agents are reasonable first-line choices in dialysis patients 1, 2, 3. They provide:

• Cardioprotective effects independent of blood pressure reduction 2
• Safety profile demonstrated in clinical trials 3
• Reduction in left ventricular hypertrophy and arterial stiffness 4

Critical caveat: The KDIGO 2021 guidelines recommend ACE inhibitors/ARBs for CKD stages G1-G4 with albuminuria 5, but explicitly state in Practice Point 3.2.6 to consider reducing or discontinuing these agents when eGFR <15 mL/min/1.73m² to reduce uremic symptoms 5. This creates a nuanced situation where these agents may be continued in ESRD if tolerated, but are not universally mandated as they are in earlier CKD stages.

Calcium Channel Blockers

Equally valid as first-line therapy 1:

• Associated with lower total and cardiovascular mortality in hemodialysis patients 4
• Effective for blood pressure control
• Particularly useful for patients prone to intradialytic hypotension (use longer-acting, once-daily formulations) 1

Beta-Blockers

Also reasonable first-line agents 2, 3:

• Decrease mortality and ventricular arrhythmias 4
• Improve left ventricular function in ESRD 4
• Essential in patients with cardiovascular disease or heart failure 3

Medication Selection Algorithm

Choose based on these patient-specific factors:

1. Intradialytic hypotension present?

   • Use nondialyzable medications (propranolol, amlodipine, carvedilol) to maintain intradialytic protection 1
   • Avoid highly dialyzable agents (atenolol, metoprolol, lisinopril) 1

2. Intradialytic hypertension present?

   • Use nondialyzable medications 1
   • Aggressively challenge dry weight 1

3. Cardiovascular disease or heart failure?

   • Beta-blockers are essential 3
   • ACE inhibitors/ARBs provide additional cardioprotection 2

4. Medication nonadherence suspected?

   • Use dialyzable agents given thrice-weekly after dialysis (lisinopril, atenolol) 3, 4
   • This supervised dosing strategy has robust blood pressure-lowering effects 2, 4

5. Stable intradialytic blood pressure?

   • Prefer once-daily, longer-acting medications to improve adherence and reduce pill burden 1
   • Administer at night to control nocturnal blood pressure and minimize intradialytic hypotension 3

Critical Pitfalls to Avoid

Hyperkalemia risk: ACE inhibitors and ARBs carry hyperkalemia risk 4. However, this can often be managed with potassium-lowering measures rather than discontinuing the medication 5. Monitor potassium closely.

Drug dialyzability confusion: There is variability and uncertainty in the literature about which drugs are truly dialyzable 1. For example, bisoprolol was recently found to be dialyzable contrary to previous belief 1. Consider intradialytic blood pressure patterns when selecting agents.

Timing matters: Individualize medication administration timing based on interdialytic blood pressure and intradialytic hypotension frequency 1. Night-time dosing is generally preferred 3.

Avoid diuretics: These are ineffective in ESRD and should not be used 4. The exception is patients with residual renal function, but this is uncommon in established ESRD.

What the Guidelines Don't Explicitly State for ESRD

The KDIGO 2020 and 2021 guidelines 1, 5 emphasize that no single medication class can be recommended over another for all dialysis patients due to patient heterogeneity and lack of comparative evidence 1. The guidelines state that "antihypertensive medications considered first-line in the general population (e.g., ACE inhibitors/ARBs and calcium channel blockers) can also be considered first-line to lower BP in patients receiving dialysis" 1.

This is a weaker recommendation than for earlier CKD stages, where ACE inhibitors/ARBs are strongly recommended for patients with albuminuria 5. In ESRD, the choice is more individualized based on comorbidities, dialyzability, and intradialytic blood pressure patterns 1.